Affymax May Run Out of Cash As Soon As 2Q, According to Analyst

Ian Somaiya, an analyst at Piper Jaffray, is suggesting that Affymax (NASDAQ: AFFY ) may run out of cash sometime in mid-2012. Somaiya reasons that Affymax has no timeline for potential re-introduction of Omontys and isn't able to estimate when it will complete the investigation surrounding the hypersensitivity issue